Moderna, Inc.
MRNA · XNASCIK 1682852fmd_0XPRKE5NEEA60RYHKPK4BHE9HJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 108 | 206 | 135 | 60 | 803 | 18,471 | 19,263 | 6,848 | 3,236 | 1,944 |
| Cost of revenue | – | – | 0 | 0 | 8 | 2,617 | 5,416 | 4,693 | 1,464 | 868 |
| Gross profit | – | – | 135 | 60 | 795 | 15,854 | 13,847 | 2,155 | 1,772 | 1,076 |
| Research and development | 275 | 410 | 454 | 496 | 1,370 | 1,991 | 3,295 | 4,845 | 4,543 | 3,132 |
| Total operating expenses | 332 | 475 | 548 | 606 | – | – | – | – | – | – |
| Operating income | (224) | (269) | (413) | (546) | (763) | 13,296 | 9,420 | (4,239) | (3,945) | (3,074) |
| Interest and investment income | 11 | 15 | 27 | 39 | 25 | 18 | 200 | 421 | 425 | 314 |
| Other non-operating income (expense) | (3) | (2) | 2 | (8) | (6) | (29) | (45) | (124) | (87) | (8) |
| Income before taxes | (215) | (256) | (384) | (515) | (744) | 13,285 | 9,575 | (3,942) | (3,607) | (2,768) |
| Income tax expense | 1 | (0) | 0 | (1) | 3 | 1,083 | 1,213 | 772 | (46) | 54 |
| Net income from continuing operations | (216) | (256) | (385) | (514) | (747) | 12,202 | 8,362 | (4,714) | (3,561) | (2,822) |
| Net income | (216) | (256) | (385) | (514) | (747) | 12,202 | 8,362 | (4,714) | (3,561) | (2,822) |
| Net income to common shareholders | (230) | (270) | (402) | (514) | (747) | – | – | – | – | – |